Skip to main content

Indaptus Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 12, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 12, 2025

INDP$2.90-7.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Unaudited Condensed Consolidated Balance Sheets

September 30, 2025December 31, 2024
Assets
Current assets:
Cash and cash equivalents$5,825,639$5,786,753
Prepaid expenses and other current assets613,354831,577
Total current assets6,438,9936,618,330
Non-current assets:
Right-of-use asset8,48782,175
Other assets - deposits to third parties392,572638,251
Total non-current assets401,059720,426
Total assets$6,840,052$7,338,756
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable and other current liabilities$2,225,639$3,309,717
Operating lease liability, current portion8,68684,164
Total current liabilities2,234,3253,393,881
Commitments and contingencies (Note 8)--
Stockholders’ equity:
Common stock: $0.01 par value, 200,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 1,641,920 shares issued and outstanding as of September 30, 2025 and 428,799 shares issued and outstanding as of December 31, 2024*16,4204,288
Preferred stock: $0.01 par value, 5,000,000 shares authorized as of September 30, 2025 and December 31, 2024; no shares issued or outstanding--
Additional paid in capital*77,764,95664,379,770
Accumulated deficit(73,175,649)(60,439,183)
Total stockholders’ equity4,605,7273,944,875
Total liabilities and stockholders’ equity$6,840,052$7,338,756
*Retroactively restated for one-for-twenty-eight share consolidation on June 27, 2025.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.